Dr David O’Reilly
British American Tobacco
Dr David O'Reilly was appointed to the Management Board of British American Tobacco as Group Scientific Director, in January 2012. He graduated from Imperial College, London in 1991 with a Ph.D. in molecular virology. He continued to pursue this area of research when he joined Advanced Technologies Cambridge, a subsidiary of British American Tobacco in 1991. In recent years at BAT, O’Reilly has been a driving force behind the creation and growth of BAT’s multidisciplinary global R&D effort in next-generation reduced-risk tobacco and nicotine products. Currently, he is leading BAT’s COVID-19 vaccine programme based on novel plant-based technology. He has also led the company’s programs in corporate social responsibility, tobacco harm reduction and scientific and public health policy and engagement. He is co-founder of the Global Tobacco and Nicotine Forum and Chairman emeritus of the GTNF Advisory Board.